Aronora

Aronora is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel drugs for blood disorders with significant unmet medical needs. The company is engaged in the commercial development of proprietary biologics, including recombinant monoclonal antibodies and enzymes, which reduce the progression of life-threatening blood clots without the harmful bleeding side effects associated with currently marketed antithrombotic drugs, enabling healthcare providers to access better medications for treating blood clots.